The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review

References

• COVID-19 Map [Internet]. Johns Hopkins coronavirus resource center [cited 2021 Jun 2]. Available from: https://coronavirus.jhu.edu/map.html .
   Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–20. doi:10.1056/NEJMoa2001017 .
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA [Internet]. 2020 [cited 2021 Sep 7]. https://jamanetwork.com/journals/jama/fullarticle/2764727 .
   Google Scholar
• García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsolo A, Bujan J, et al. An updated review of sars-cov-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9:433.5. doi:10.3390/vaccines9050433 .
   Web of Science ®Google Scholar
• McGill COVID-19 vaccine tracker [Internet]. [cited 2021 June 5]. https://covid19.trackvaccines.org/ .
   Google Scholar
• Izda V, Jeffries MA, Sawalha AH. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634. doi:10.1016/j.clim.2020.108634 .
   PubMed Web of Science ®Google Scholar
• Graham BS, Mascola JR, Fauci AS. Novel vaccine technologies: essential components of an adequate response to emerging viral diseases. JAMA. 2018;319:1431. doi:10.1001/jama.2018.0345 .
   PubMed Web of Science ®Google Scholar
• Bashirullah A, Cooperstock RL, Lipshitz HD. Spatial and temporal control of RNA stability. Proc Natl Acad Sci. 2001;98:7025–28. doi:10.1073/pnas.111145698 .
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich BM, Ketova T, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1–11. doi:10.1016/j.omtn.2019.01.013 .
   PubMedGoogle Scholar
• Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–50. doi:10.1056/NEJMoa2027906 .
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2 preliminary report. N Engl J Med. 2020;383:1920–31. doi:10.1056/NEJMoa2022483 .
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–55. doi:10.1056/NEJMoa2024671 .
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4 .
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586:578–82. doi:10.1038/s41586-020-2608-y .
   PubMed Web of Science ®Google Scholar
• Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, Zuijdgeest D, de Wilde AH, Koornneef A, Verwilligen A, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses. Npj Vacc. 2020;5:91. doi:10.1038/s41541-020-00243-x .
   PubMed Web of Science ®Google Scholar
• Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, et al. Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2021;39:3081–101. doi:10.1016/j.vaccine.2020.09.018 .
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–97. doi:10.1016/S0140-6736(20)31866-3 .
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32. doi:10.1056/NEJMoa2026920 .
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, Mao H, Xin Q, Chu K, Han W, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial [Internet]. Public Global Health. 2020 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2020.07.31.20161216 .
   Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951. doi:10.1001/jama.2020.15543 .
   PubMed Web of Science ®Google Scholar
• Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354 .
   PubMed Web of Science ®Google Scholar
• Robbins T, Baitule S, Kyrou I, Ray P, Morgan N, Berry L, Randeva H. SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort. Clin Med. 2021;21:e243.2–e243. doi:10.7861/clinmed.Let.21.2.6 .
   Web of Science ®Google Scholar
• Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384:2212–18. doi:10.1056/NEJMoa2105000 .
   PubMed Web of Science ®Google Scholar
• Vaccine efficacy, effectiveness and protection. [cited 2021 Dec 11]. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection .
   Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–89. doi:10.1056/NEJMc2104974 .
   PubMed Web of Science ®Google Scholar
• Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–77. doi:10.1016/S0140-6736(21)00448-7 .
   PubMed Web of Science ®Google Scholar
• Andrejko KL, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, Jain S, Lewnard JA. Prevention of COVID-19 by mRNA-based vaccines within the general population of California [Internet]. Epidemiology. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.08.21255135 .
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. doi:10.1056/NEJMoa2035389 .
   PubMed Web of Science ®Google Scholar
• Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021;384:1775–77. doi:10.1056/NEJMc2101951 .
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, Simmons R, Cottrell S, Roberts R, O’Doherty M, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England [Internet]. Infect Dis (except HIV/AIDS); 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.03.01.21252652 .
   Google Scholar
• Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population – first results from a cohort study in Southern Sweden [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.20.21254636 .
   Google Scholar
• Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, Steiner J, Schechter-Perkins EM, Duffy E, Ragan EJ, et al. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.03.30.21254655 .
   Google Scholar
• Britton A, Jacobs Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich HY, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks — Connecticut, December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70:396–401. doi:10.15585/mmwr.mm7011e3 .
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–23. doi:10.1056/NEJMoa2101765 .
   PubMed Web of Science ®Google Scholar
• Daniel W, Nivet M, Warner J, Podolsky DK. Early evidence of the effect of SARS-CoV-2 vaccine at one medical center. N Engl J Med. 2021;384:1962–63. doi:10.1056/NEJMc2102153 .
   PubMed Web of Science ®Google Scholar
• Dyer O. Covid-19: moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds. BMJ. 2021;n888. doi:10.1136/bmj.n888 .
   PubMedGoogle Scholar
• de Faria E, Guedes AR, Oliveira MS, de Godoy Moreira MV, Maia FL, Dos Santos Barboza A, Leme MD, Letaif LSH, Miethke-Morais A, Bonfá E, et al. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.12.21255308 .
   Google Scholar
• Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett S, Aylin P, Sandall T, Goodman I, Redhead J, et al. North West London Covid-19 vaccination programme: real-world evidence for vaccine uptake and effectiveness [Internet]. Health Informatics. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.08.21254580 .
   Google Scholar
• Goldberg Y, Mandel M, Woodbridge Y, Fluss R, Novikov I, Yaari R, Ziv A, Freedman L, Huppert A. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: a three-month nationwide experience from Israel [Internet]. Epidemiology. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.20.21255670 .
   Web of Science ®Google Scholar
• Guijarro C, Galán I, Martínez-ponce D, Pérez-Fernández E, Goyanes MJ, Castilla V, Velasco M. SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 vaccine [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.03.24.21254238 .
   Google Scholar
• Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–35. doi:10.1016/S0140-6736(21)00790-X .
   PubMed Web of Science ®Google Scholar
• Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz WL, de Oliveira RD, Da Silva PV, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.07.21255081 .
   Google Scholar
• Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.02.01.21250957 .
   Google Scholar
• Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, Ferris M, Wright J, Quinnell N, Shaw A, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 2021;10:e68808. doi:10.7554/eLife.68808 .
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72–74. doi:10.1016/S0140-6736(20)32623-4 .
   PubMed Web of Science ®Google Scholar
• Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus BJ, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN J [Internet]. 2021 [cited 2021 Sep 7]. https://www.ssrn.com/abstract=3779160 .
   Google Scholar
• Lillie PJ, O’Brien P, Lawtie M, Jessop S, Easom NJW, Patmore R. First dose of BNT162b2 mRNA vaccine in a healthcare worker cohort is associated with reduced symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis. 2021;73(10):1906-1908. doi: 10.1093/cid/ciab351.
   PubMedGoogle Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81. doi:10.1016/S0140-6736(21)00234-8 .
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885–98. doi:10.1056/NEJMoa2102214 .
   PubMed Web of Science ®Google Scholar
• Mason T, Whitston M, Hodgson J, Watkinson RE, Lau Y-S, Abdulrazeg O, Sutton M. Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England [Internet]. Public Global Health. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.19.21255461 .
   Google Scholar
• McEllistrem MC, Clancy CJ, Buehrle DJ, Lucas A, Decker BK. Single dose of an mRNA severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;Sep 15;73(6):e1365-e1367. doi: 10.1093/cid/ciab263.
   PubMedGoogle Scholar
• Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A. COVID-19 registries study group. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.08.21255055 .
   Google Scholar
• Mor V, Gutman R, Yang X, White EM, McConeghy KW, Feifer RA, Blackman CR, Kosar CM, Bardenheier BH, Gravenstein SA. Short‐term impact of nursing home SARS‐CoV ‐2 vaccinations on new infections, hospitalizations, and deaths. J Am Geriatr Soc. 2021;69:2063–69. doi:10.1111/jgs.17176 .
   PubMed Web of Science ®Google Scholar
• Moustsen-Helms IR, Emborg H-D, Nielsen J, Nielsen KF, Krause TG, Mølbak K, Møller KL, Berthelsen A-SN, Valentiner-Branth P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers – a Danish cohort study [Internet]. Epidemiology. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252200 .
   Google Scholar
• Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJM, O’Horo JC, Virk A, Swift MD, Badley AD, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.02.15.21251623 .
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577 .
   PubMed Web of Science ®Google Scholar
• Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, Jones J, House T, VanSteenHouse H, Bell I, et al. Impact of vaccination on new SARS-CoV-2 infections in the UK [Internet]. Infect Dis (Except HIV/AIDS). 2021 [[cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.22.21255913 .
   Google Scholar
• ScottA R, Roberson S, Blackmore C. Outcomes of COVID-19 vaccination efforts in Florida from December 14, 2020 to March 15, 2021 on older individuals [Internet]. Public Global Health. 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.05.21254722 .
   Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. doi:10.1056/NEJMoa2101544 .
   PubMed Web of Science ®Google Scholar
• Salazar PD, Link N, Lamarca K, Santillana M. High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities [Internet]. Review. 2021 [cited 2021 Sep 7]. https://www.researchsquare.com/article/rs-355257/v1 .
   Google Scholar
• Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.02.25.21252477 .
   Google Scholar
• Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, Breeher L, Binnicker M, Berbari EF. Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis. 2021;ciab229. doi:10.1093/cid/ciab229 .
   Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. doi:10.15585/mmwr.mm7013e3 .
   PubMed Web of Science ®Google Scholar
• Vahidy FS, Pischel L, Tano ME, Pan AP, Boom ML, Sostman HD, Nasir K, Omer SB. Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the United States [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.04.21.21255873 .
   Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91 .
   PubMed Web of Science ®Google Scholar
• Yelin I, Katz R, Herzel E, Berman-Zilberstein T, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities [Internet]. Infect Dis (Except HIV/AIDS). 2021 [cited 2021 Sep 7]. http://medrxiv.org/lookup/doi/10.1101/2021.03.16.21253686 .
   Google Scholar
• Tracking SARS-CoV-2 variants. [cited 2021 Dec 11. https://www.who.int/emergencies/what-we-do/tracking-SARS-CoV-2-variants .
   Google Scholar
• Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21:e26–35. doi:10.1016/S1473-3099(20)30773-8 .
   PubMed Web of Science ®Google Scholar
• Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201:1607–10. doi:10.1086/652404 .
   PubMed Web of Science ®Google Scholar
• World Health Organization. Correlates of vaccine-induced protection: methods and implications [Internet]. World Health Organization; 2013 [cited 2021 Sep 15]. https://apps.who.int/iris/handle/10665/84288 .
   Google Scholar
• Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2:e279–80. doi:10.1016/S2666-5247(21)00069-0 .
   PubMedGoogle Scholar
• Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, Muhsen K. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. Infect Dis (Except HIV/AIDS). 2021. doi:10.1101/2021.01.27.21250612 .
   Google Scholar
• Israel to extend COVID vaccine drive to anyone over 16 starting Thursday [Internet]. Haaretz. [cited 2021 Sep 15]. https://www.haaretz.com/israel-news/israel-to-extend-covid-vaccine-drive-to-anyone-over-16-starting-thursday-1.9507884.
   Google Scholar
• Isolamento | Governo do Estado de São Paulo [Internet]. Isolamento | governo do Estado de São Paulo. [cited 2021 Sep 15]. https://www.saopaulo.sp.gov.br/coronavirus/isolamento .
   Google Scholar
• Cidade de de São Paulo. Monitoramento de novas variantes de SARS-CoV-2 no Município de São Paulo. 2021 Mar 26. https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/situacao_covid19_03_26_03_2021.pdf .
   Google Scholar
• Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O’Horo JC, Virk A, Swift MD, Halamka J, Badley AD, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRxiv. 2021 Aug 06:21261707. doi:10.1101/2021.08.06.21261707 .
   Google Scholar
• Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, House T, Hay J, Bell J, Newton J, et al. Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Epidemiology. 2021. doi:10.1101/2021.08.18.21262237 .
   Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94. doi:10.1056/NEJMoa2108891 .
   PubMed Web of Science ®Google Scholar